PURPOSE 365: Yearly PrEP Injection Could Be the Future of HIV Prevention
Our team of scientists are studying an investigational once-yearly HIV PrEP (pre-exposure prophylaxis) medicine, lenacapavir, to see if it helps to reduce the chance of getting HIV through sex.
In this type of clinical study, all participants in the study will receive the investigational medicine. It’s given as 2 injections into the muscle once every 52 weeks (once yearly).
What Does the Study Involve?
First, you'll come to a participating clinic to review, complete, and sign an informed consent form. During this initial visit, you will be tested for HIV and have other lab work completed. Then, staff will ask you some questions to make sure you meet all the eligibility criteria to participate in the study.
- If you do not have HIV and meet all the eligibility criteria, you may be able to enroll in the study
- If you are confirmed to have HIV, we will help you find HIV care in your community
.svg){kind=icon}
- All participants will receive lenacapavir
- You will receive 2 injections given once every 52 weeks (once yearly)
- This study will last until lenacapavir is approved as a once-yearly dosing option or until Gilead decides to discontinue the study
- After 1 year, participants will be offered the option to continue receiving lenacapavir once every 52 weeks
- The study visits are 4-13 weeks apart, with 4-7 visits per year